Based on the Traws Pharma Inc stock forecast from 0 analysts, the average analyst target price for Traws Pharma Inc is not available over the next 12 months. Traws Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Traws Pharma Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Traws Pharma Inc’s stock price was USD 1.10. Traws Pharma Inc’s stock price has changed by -21.43% over the past week, -48.36% over the past month and -93.31% over the last year.
No recent analyst target price found for Traws Pharma Inc
No recent average analyst rating found for Traws Pharma Inc
Company Overview Traws Pharma Inc
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Read Less
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address...Read More
Frequently Asked Questions About Traws Pharma Inc (TRAW) Stock
Stock Target Advisor's fundamental analysis for Traws Pharma Inc's stock is Bearish.
Unfortunately we do not have enough data on TRAW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TRAW's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on TRAW's stock to indicate if its overvalued.
The last closing price of TRAW's stock was USD 1.10.
The most recent market capitalization for TRAW is USD 9.87M.
Unfortunately we do not have enough analyst data on TRAW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Traws Pharma Inc's stock.
As per our most recent records Traws Pharma Inc has 0 Employees.
Traws Pharma Inc's registered address is 12 Penns Trail, Newtown, PA, United States, 18940.
You can get more information about it from Traws Pharma Inc's website at https://www.trawspharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Traws Pharma Inc (TRAW) Stock
Stock Target Advisor's fundamental analysis for Traws Pharma Inc's stock is Bearish.
Unfortunately we do not have enough data on TRAW's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TRAW's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on TRAW's stock to indicate if its overvalued.
The last closing price of TRAW's stock was USD 1.10.
The most recent market capitalization for TRAW is USD 9.87M.
Unfortunately we do not have enough analyst data on TRAW's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Traws Pharma Inc's stock.
As per our most recent records Traws Pharma Inc has 0 Employees.
Traws Pharma Inc's registered address is 12 Penns Trail, Newtown, PA, United States, 18940.
You can get more information about it from Traws Pharma Inc's website at https://www.trawspharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRAW !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
